Switching biologics for psoriasis

Br J Dermatol. 2010 Oct;163(4):667-9. doi: 10.1111/j.1365-2133.2010.09999.x.
No abstract available

Publication types

  • Editorial
  • Introductory Journal Article

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Biological Products / therapeutic use*
  • Dermatologic Agents / therapeutic use*
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Treatment Failure

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Dermatologic Agents
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Adalimumab
  • Etanercept